# Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

> **NCT06245356** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 73 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Metastatic Gastroesophageal Adenocarcinoma
- DPD Deficiency

## Interventions

- **DRUG:** Lonsurf
- **DRUG:** Oxaliplatin
- **DRUG:** Panitumumab
- **DRUG:** Bevacizumab
- **DRUG:** Trastuzumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06245356
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2026-10-22
- **Final completion:** 2028-10-21
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245356, "Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06245356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*